Table 5 Review of the literature regarding the association between TAMs in sarcoma and clinical outcome.
From: Macrophage numbers in the marginal area of sarcomas predict clinical prognosis
Author | Number of cases | Examined factors | Results |
|---|---|---|---|
Chan-Han Lee et al. 28 | 149 LMS cases | Patients categorized into 3 groups according to the number of CD68 + and CD163 + macrophages in a 0.6 mm tumor core | High density of CD68 + and CD163 + was correlated with poor disease specific survival in nongynecological leiomyosarcomas |
Kristen et al. 29 | 52 LMS cases | Number of CD163 + macrophages. Expression of CD163, CD16, and cathepsin L was evaluated as “colony stimulating factor-associated protein” | Increased levels of CD163 + tended to decrease OS, but the difference was not statistically significant. High expression of CD16, cathepsin L, and all (CD16, CD163, cathepsin L) correlated with worse OS of patients with gynecological leiomyosarcoma |
Nabesima et al.30 | 78 myxoid liposarcoma cases | Number of CD68 + and CD163 + macrophages in 10 random high-power fields | High levels of CD68 + and CD163 + were associated with poorer overall survival |
Oike et al.31 | 36 synovial sarcoma cases | Lymphocytes (CD4 + , CD8 + , and FOXP3 +) and macrophages (CD163 +) were counted in five high-power fields. Expression of PD-L1 by sarcoma cells was examined | High numbers of CD163 + macrophages were associated with significantly worse OS and progression-free survival |
Shiraishi et al.32 | 62 UPS cases | The number of Iba1 + and CD163 + macrophages in 10 randomly selected high-power fields was counted | A high percentage of CD163 + macrophages (CD163 + /Iba1 +) was associated with poorer OS |
Komohara et al.4 | 28 UPS cases | The number of macrophages (Iba1 + , CD163 + , and CD204 +) and CD8 + lymphocytes in five randomly selected high-power views was counted | A high number of CD163 + and CD204 + macrophages tended to indicate worse DFS and OS, but result was not significant |
